Potent tetrahydroquinolone eliminates apicomplexan parasites

McPhille, M. J. et al. (2020) Potent tetrahydroquinolone eliminates apicomplexan parasites. Frontiers in Cellular and Infection Microbiology, 10, 203. (doi: 10.3389/fcimb.2020.00203) (PMID:32626661) (PMCID:PMC7311950)

[img] Text
229004.pdf - Published Version
Available under License Creative Commons Attribution.



Apicomplexan infections cause substantial morbidity and mortality, worldwide. New, improved therapies are needed. Herein, we create a next generation anti-apicomplexan lead compound, JAG21, a tetrahydroquinolone, with increased sp3-character to improve parasite selectivity. Relative to other cytochrome b inhibitors, JAG21 has improved solubility and ADMET properties, without need for pro-drug. JAG21 significantly reduces Toxoplasma gondii tachyzoites and encysted bradyzoites in vitro, and in primary and established chronic murine infections. Moreover, JAG21 treatment leads to 100% survival. Further, JAG21 is efficacious against drug-resistant Plasmodium falciparum in vitro. Causal prophylaxis and radical cure are achieved after P. berghei sporozoite infection with oral administration of a single dose (2.5 mg/kg) or 3 days treatment at reduced dose (0.625 mg/kg/day), eliminating parasitemia, and leading to 100% survival. Enzymatic, binding, and co-crystallography/pharmacophore studies demonstrate selectivity for apicomplexan relative to mammalian enzymes. JAG21 has significant promise as a pre-clinical candidate for prevention, treatment, and cure of toxoplasmosis and malaria.

Item Type:Articles
Additional Information:This work was supported by NIAID NIH DMID U01 AI082180 (RM) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant #5T35DK062719-28 to FH. This was also supported by National Institutes of Health (NIH) contract number HHNS272200900007C, NIH. National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID) award numbers R01AI071319(NIAID) and R01AI027530 (NIAID) (RM); NIAID contract Number HHNS272200900007C; NIAID award number U19AI110819 (HL):NIAID award number U01 AI077887(NIAID) and Defense Threat Reduction Agency award number 13-C-0055, and Department of Defense award numbers W911NF-09-D0001 and W911SR-07-C0101(MH). This work was also supported by R01 AI128356 to SNM. The work also was supported by the Bill and Melinda Gates Foundation (BMGF, OPP1150755) (RKP). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. #DGE-1656466 awarded to KR. RJ was funded by a Ph.D scholarship by the Wellcome Trust (109158/B/15/Z).
Glasgow Author(s) Enlighten ID:Hargrave, Dr Kerrie
Authors: McPhille, M. J., Zhou, Y., Hickman, M., R., Gordon, J. A., Weber, C., R., Li, Q., Lee, P., J., Amporndanai, K., Johnson, R. M., Darby, H., Woods, S., Li, Z.-h., Priestley, R. S., Ristroph, K. D., Biering, S. B., Bissati, K. E., Hwang, S., Hakim, F. E., Dovgin, S. M., Lykins, J. D., Roberts, L., Hargrave, K., Cong, H., Sinai, A. P., Muench, S. P., Dubey, J. P., Prud'homme, R. K., Lorenzi, H. A., Biagini, G. A., Moreno, S. N., Roberts, C. W., Antonyuk, S. V., Fishwick, C. W.G., and McLeod, R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Frontiers in Cellular and Infection Microbiology
Publisher:Frontiers Media
ISSN (Online):2235-2988
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Frontiers in Cellular and Infection Microbiology 10:203
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record